Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 627-653

  Forrester, Steven J ^a   Kawai, Tatsuo ^a   O'Brien, Shannon ^b   Thomas, Walter ^b   Harris, Raymond C ^c   Eguchi, Satoru ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Angiotensin II; Endothelium; Heart; Kidney; Signal transduction; Vascular smooth muscle

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOTENSIN II; ANTISENSE OLIGONUCLEOTIDE; BETACELLULIN; CHOLINE KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIREGULIN; ERLOTINIB; FOCAL ADHESION KINASE 2; G PROTEIN COUPLED RECEPTOR; GEFITINIB; GELATINASE A; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; KALLIKREIN; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; UNINDEXED DRUG;

ABDOMINAL AORTA ANEURYSM; ACUTE GLOMERULONEPHRITIS; ACUTE KIDNEY FAILURE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; GLOMERULOSCLEROSIS; HEART ARRHYTHMIA; HEART FIBROBLAST; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RUPTURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; OXYGEN-INDUCED RETINOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; URETER OBSTRUCTION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; ANIMAL; METABOLISM; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84954168435     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-070115-095427     Document Type: Article

References (171)

1. Zeng F, Harris RC. 2014. Epidermal growth factor, from gene organization to bedside. Semin. Cell Dev. Biol. 28:2-11
2. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-37
3. Wieduwilt MJ, Moasser MM. 2008. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol. Life Sci. 65:1566-84
4. Arteaga CL, Engelman JA. 2014. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25:282-303
5. Makki N, Thiel KW, Miller FJ Jr. 2013. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int. J. Mol. Sci. 14:20597-613
6. Schreier B, GekleM,Grossmann C. 2014. Role of epidermal growth factor receptor in vascular structure and function. Curr. Opin. Nephrol. Hypertens. 23:113-21
7. Leserer M, Gschwind A, Ullrich A. 2000. Epidermal growth factor receptor signal transactivation. IUBMB Life 49:405-9
8. Wetzker R, Bohmer FD. 2003. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat. Rev. Mol. Cell Biol. 4:651-57
9. George AJ, Purdue BW, Gould CM, Thomas DW, Handoko Y, et al. 2013. A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. J. Cell Sci. 126:5377-90
10. George AJ, Hannan RD, Thomas WG. 2013. Unravelling the molecular complexity ofGPCR-mediated EGFR transactivation using functional genomics approaches. FEBS J. 280:5258-68
11. Ohtsu H, Dempsey PJ, Eguchi S. 2006. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 291:C1-10
12. Elliott KJ, Bourne AM, Takayanagi T, Takaguri A, Kobayashi T, et al. 2013. ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells. J. Mol. Cell Cardiol. 62:1-7
13. Overland AC, Insel PA. 2015. Heterotrimeric G proteins directly regulate MMP14/membrane type-1 matrix metalloprotease: A novel mechanism forGPCR-EGFRtransactivation. J. Biol. Chem. 290:9941-47
14. Ushio-Fukai M, Alexander RW. 2006. Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle. Hypertension 48:797-803
15. Tilley DG. 2011. Gprotein-dependent andGprotein-independent signaling pathways and their impact on cardiac function. Circ. Res. 109:217-30
16. Blobel CP. 2005. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6:32-43
17. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A. 2012. The role of ADAM-mediated shedding in vascular biology. Eur. J. Cell Biol. 91:472-85
18. Mehta PK, Griendling KK. 2007. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292:C82-97
19. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. 2007. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin. Sci. 112:417-28
20. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. 2001. Activation of MAPKs by angiotensin II in vascular smooth muscle cells: metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J. Biol. Chem. 276:7957-62
21. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, et al. 1998. Calcium-dependent epidermal growth factor receptor transactivationmediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J. Biol. Chem. 273:8890-96
22. BrietM, Schiffrin EL. 2013. Treatment of arterial remodeling in essential hypertension. Curr. Hypertens. Rep. 15:3-9
23. Mifune M, Ohtsu H, Suzuki H, Frank GD, Inagami T, et al. 2004. Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 287:C807-13
24. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. 2014. Angiotensin II and vascular injury. Curr. Hypertens. Rep. 16:431
25. Seshiah PN,Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. 2002. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 91:406-13
26. Touyz RM, Wu XH, He G, Salomon S, Schiffrin EL. 2002. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 39:479-85
27. Ohtsu H, Higuchi S, Shirai H, Eguchi K, Suzuki H, et al. 2008. Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells. Endocrinology 149:3569-75
28. IwasakiH, Eguchi S, Ueno H, Marumo F, Hirata Y. 1999. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 140:4659-68
29. Schreier B, Dohler M, Rabe S, Schneider B, Schwerdt G, et al. 2011. Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smoothmuscle cells from mice with targeted deletion of ErbB1. Arterioscler. Thromb. Vasc. Biol. 31:1643-52
30. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, et al. 2006. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 26:e133-37
31. Li F, Malik KU. 2005. Angiotensin II-induced Akt activation through the epidermal growth factor receptor in vascular smooth muscle cells is mediated by phospholipid metabolites derived by activation of phospholipase D. J. Pharmacol. Exp. Ther. 312:1043-54
32. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. 2009. Independent arrestin2 and Gq/protein kinase Cpathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J. Biol. Chem. 284:11953-62
33. Abdallah RT, Keum JS, El-Shewy HM, Lee MH, Wang B, et al. 2010. Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smoothmuscle through direct activation of protease-activated receptors. J. Biol. Chem. 285:35206-15
34. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. 2004. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ. Res. 94:68-76
35. Hao L,Nishimura T,WoH, Fernandez-Patron C. 2006. Vascular responses to 1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler. Thromb. Vasc. Biol. 26:819-25
36. Nagareddy PR,Chow FL, Hao L,WangX,Nishimura T, et al. 2009. Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis. Cardiovasc. Res. 84:368-77
37. Gratton JP, Bernatchez P, Sessa WC. 2004. Caveolae and caveolins in the cardiovascular system. Circ. Res. 94:1408-17
38. Takaguri A, Shirai H, Kimura K, Hinoki A, Eguchi K, et al. 2011. Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. J. Mol. Cell Cardiol. 50:545-51
39. Takayanagi T, Crawford KJ, Kobayashi T, Obama T, Tsuji T, et al. 2014. Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase. Clin. Sci. 126:785-94
40. Grossmann C, Krug AW, Freudinger R, Mildenberger S, Voelker K, Gekle M. 2007. Aldosteroneinduced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 292:E1790-800
41. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, et al. 2004. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109:2792-800
42. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. 2005. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 97:434-42
43. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, et al. 2008. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler. Thromb. Vasc. Biol. 28:1511-18
44. Meinel S, GekleM,Grossmann C. 2014. Mineralocorticoid receptor signaling: crosstalk with membrane receptors and other modulators. Steroids 91:3-10
45. Limor R, Kaplan M, Sharon O, Knoll E, Naidich M, et al. 2009. Aldosterone up-regulates 12-and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. J. Cell Biochem. 108:1203-10
46. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, et al. 2010. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 55:1476-83
47. Frank GD, Mifune M, Inagami T, Ohba M, Sasaki T, et al. 2003. Distinct mechanisms of receptor and nonreceptor tyrosine kinase activation by reactive oxygen species in vascular smooth muscle cells: role of metalloprotease and protein kinase C-. Mol. Cell. Biol. 23:1581-89
48. Jagadeesha DK, Takapoo M, Banfi B, Bhalla RC, Miller FJ Jr. 2012. Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc. Res. 93:406-13
49. Suc I, Meilhac O, Lajole-Mazenc I, Vandaele J, Jurgens G, et al. 1998. Activation of EGF receptor by oxidized LDL. FASEB J. 12:665-71
50. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. 2000. Mechanical stretch stimulates growth of vascular smoothmuscle cells via epidermal growth factor receptor. Am. J. Physiol. Cell Physiol. 278:H521-29
51. Konishi A, Berk BC. 2003. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J. Biol. Chem. 278:35049-56
52. Eguchi S, Frank GD, Mifune M, Inagami T. 2003. Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem. Soc. Trans. 31:1198-202
53. Daub H, Weiss FU, Wallasch C, Ullrich A. 1996. Role of transactivation of theEGFreceptor in signalling by G-protein-coupled receptors. Nature 379:557-60
54. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, et al. 2003. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. 22:2704-16
55. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. 2002. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106:909-12
56. Kagiyama S, Qian K, Kagiyama T, Phillips MI. 2003. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 41:824-29
57. Lucchesi PA, Sabri A, Belmadani S, Matrougui K. 2004. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone inmousemesenteric resistance arteries. Circulation 110:3587-93
58. Nagareddy PR,MacLeod KM, McNeill JH. 2010. GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats. Cardiovasc. Res. 87:177-86
59. UluN,MulderGM, Vavrinec P, Landheer SW,Duman-Dalkilic B, et al. 2013. Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. J. Pharmacol. Exp. Ther. 345:393-403
60. Schreier B, Rabe S, Schneider B, Bretschneider M, Rupp S, et al. 2013. Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension 61:333-40
61. Takayanagi T, Kawai T, Forrester SJ, Obama T, Tsuji T, et al. 2015. Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II. Hypertension 65:1349-55
62. Chen J, Chen JK, Nagai K, Plieth D, Tan M, et al. 2012. EGFR signaling promotes TGF-dependent renal fibrosis. J. Am. Soc. Nephrol. 23:215-24
63. Chan SL, Umesalma S, Baumbach GL. 2015. Epidermal growth factor receptor is critical for angiotensin II-mediated hypertrophy in cerebral arterioles. Hypertension 65:806-12
64. Obama T, Takayanagi T, Kobayashi T, Bourne AM, Elliott KJ, et al. 2015. Vascular induction of a disintegrin and metalloprotease 17 by angiotensin II through hypoxia inducible factor 1. Am. J. Hypertens. 28:10-14
65. Lundstam U, Hagg U, Sverrisdottir YB, Svensson LE, Gan LM. 2007. Epidermal growth factor levels are related to diastolic blood pressure and carotid artery stiffness. Scand. Cardiovasc. J. 41:308-12
66. Chan AK, Kalmes A, Hawkins S, Daum G, Clowes AW. 2003. Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. J. Vasc. Surg. 37:644-49
67. Pastore CJ, Isner JM, Bacha PA, Kearney M, Pickering JG. 1995. Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo. Results of local versus systemic administration. Circ. Res. 77:519-29
68. Takaguri A, Kimura K, Hinoki A, Bourne AM, Autieri MV, Eguchi S. 2011. A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 57:841-45
69. Zhang H, Sunnarborg SW, McNaughton KK, Johns TG, Lee DC, Faber JE. 2008. Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling. Circ. Res. 102:1275-85
70. Stanic B, Pandey D, Fulton DJ, Miller FJ Jr. 2012. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32:2452-60
71. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. 2006. The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. Atherosclerosis 186:38-53
72. Oksala N, Levula M, AirlaN, Pelto-Huikko M, OrtizRM, et al. 2009. ADAM-9, ADAM-15, andADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries-Tampere vascular study. Ann. Med. 41:279-90
73. Spin JM, Hsu M, Azuma J, Tedesco MM, Deng A, et al. 2011. Transcriptional profiling and network analysis of the murine angiotensin II-induced abdominal aortic aneurysm. Physiol. Genom. 43:993-1003
74. Satoh H, Nakamura M, Satoh M, Nakajima T, Izumoto H, et al. 2004. Expression and localization of tumour necrosis factor-and its converting enzyme in human abdominal aortic aneurysm. Clin. Sci. 106:301-6
75. Kaneko H, Anzai T, Horiuchi K, Kohno T, Nagai T, et al. 2011. Tumor necrosis factor-converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis 218:470-78
76. ObamaT,Tsuji T, KobayashiT, Fukuda Y, Takayanagi T, et al. 2014. Epidermal growth factor receptor inhibitor protects abdominal aortic aneurysm in a mouse model. Clin. Sci. 128:559-65
77. Montiel M, de la Blanca EP, Jimenez E. 2005. Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 327:971-78
78. Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, et al. 2011. Migration of growth factorstimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat. Commun. 2:229
79. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. 2011. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arterioscler. Thromb. Vasc. Biol. 31:1898-907
80. Al-Ani B, Hewett PW, Cudmore MJ, Fujisawa T, Saifeddine M, et al. 2010. Activation of proteinaseactivated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Hypertension 55:689-97
81. Chen K, Thomas SR, Albano A, Murphy MP, Keaney JF Jr. 2004. Mitochondrial function is required for hydrogen peroxide-induced growth factor receptor transactivation and downstream signaling. J. Biol. Chem. 279:35079-86
82. Cheng J,Garcia V, Ding Y, Wu CC, Thakar K, et al. 2012. Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 32:1917-24
83. Vacaresse N, Lajoie-Mazenc I, Auge N, Suc I, Frisach MF, et al. 1999. Activation of epithelial growth factor receptor pathway by unsaturated fatty acids. Circ. Res. 85:892-99
84. Wang Y, RocheO,XuC,MoriyamaEH, Heir P, et al. 2012. Hypoxia promotes ligand-independentEGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. PNAS 109:4892-97
85. Oliveira CJ, Schindler F, Ventura AM, Morais MS, Arai RJ, et al. 2003. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic. Biol. Med. 35:381-96
86. Yamamoto K, Kakino A, Takeshita H, Hayashi N, Li L, et al. 2015. Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptor. FASEB J. 29:3342-56
87. Batenburg WW, Jansen PM, van den Bogaerdt AJ, AHJ Danser. 2012. Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase. Cardiovasc. Res. 94:136-43
88. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. 2004. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109:1795-801
89. Helle F, Jouzel C, Chadjichristos C, Placier S, Flamant M, et al. 2009. Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. Am. J. Physiol. Ren. Physiol. 297:F191-99
90. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F. 2011. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 57:238-44
91. Galan M, Kassan M, Choi SK, Partyka M, Trebak M, et al. 2012. A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 60:71-80
92. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA,Matrougui K. 2008. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57:1629-37
93. Hewing NJ,Weskamp G, Vermaat J, Farage E, Glomski K, et al. 2013. Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice. Invest. Ophthalmol. Vis. Sci. 54:864-70
94. WeskampG,Mendelson K, Swendeman S, LeGall S, Ma Y, et al. 2010. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ. Res. 106:932-40
95. Wilson CL, Gough PJ, Chang CA, Chan CK, Frey JM, et al. 2013. Endothelial deletion of ADAM17 in mice results in defective remodeling of the semilunar valves and cardiac dysfunction in adults. Mech. Dev. 130:272-89
96. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. 2002. Adenoviraldirected expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ. Res. 90:135-42
97. Smith NJ, Chan HW, Qian H, Bourne AM, Hannan KM, et al. 2011. Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy. Hypertension 57:973-80
98. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8:35-40
99. De Giusti VC, Nolly MB, Yeves AM, Caldiz CI, Villa-Abrille MC, et al. 2011. Aldosterone stimulates the cardiac Na+/H+ exchanger via transactivation of the epidermal growth factor receptor. Hypertension 58:912-19
100. Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, et al. 2009. Tumor necrosis factor-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 54:575-82
101. Zeng SY,ChenX,Chen SR, Li Q,WangYH, et al. 2013. Upregulation ofNox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression. Can. J. Cardiol. 29:1310-19
102. Noma T, Lemaire A,Naga Prasad SV, Barki-Harrington L, Tilley DG, et al. 2007.-arrestin-mediated1-adrenergic receptor transactivation of theEGFRconfers cardioprotection. J. Clin. Investig. 117:2445-58
103. Kim IM, Tilley DG, Chen J, Salazar NC,Whalen EJ, et al. 2008. blockers alprenolol and carvedilol stimulate arrestin-mediated EGFR transactivation. PNAS 105:14555-60
104. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. 2010. Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci. Signal. 3:ra46
105. Miao Y, Bi XY, Zhao M, Jiang HK, Liu JJ, et al. 2015. Acetylcholine inhibits tumor necrosis factor activated endoplasmic reticulum apoptotic pathway via EGFR-PI3K signaling in cardiomyocytes. J. Cell Physiol. 230:767-74
106. Grisanti LA, Talarico JA, Carter RL, Yu JE, Repas AA, et al. 2014. Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt. J. Mol. Cell Cardiol. 72:39-51
107. Talarico JA, Carter RL, Grisanti LA, Yu JE, Repas AA, Tilley DG. 2014. Adrenergic receptordependent alterations in murine cardiac transcript expression are differentially regulated by gefitinib in vivo. PLOS ONE 9:e99195
108. Wang D, Yu X, Cohen RA, Brecher P. 2000. Distinct effects of N-acetylcysteine and nitric oxide on angiotensin II-induced epidermal growth factor receptor phosphorylation and intracellular Ca2+ levels. J. Biol. Chem. 275:12223-30
109. Sabri A, Short J, Guo J, Steinberg SF. 2002. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ. Res. 91:532-39
110. Seta K, Sadoshima J. 2003. Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor. J. Biol. Chem. 278:9019-26
111. Chen CH, Cheng TH, Lin H, Shih NL, Chen YL, et al. 2006. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol. Pharmacol. 69:1347-55
112. Cai J, Yi FF, Yang L, Shen DF, Yang Q, et al. 2009. Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension 53:539-48
113. Zhai P, Galeotti J, Liu J, Holle E, Yu X, et al. 2006. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ. Res. 99:528-36
114. Messaoudi S, Zhang AD, Griol-Charhbili V, Escoubet B, Sadoshima J, et al. 2012. The epidermal growth factor receptor is involved in angiotensin II but not aldosterone/salt-induced cardiac remodelling. PLOS ONE 7:e30156
115. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, et al. 2012. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat. Med. 18:1429-33
116. Li C, Zhang YY, Frieler RA, Zheng XJ, Zhang WC, et al. 2014. Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLOS ONE 9:e110950
117. Schreier B, Rabe S, Winter S, Ruhs S, Mildenberger S, et al. 2014. Moderate inappropriately high aldosterone/NaCl constellation in mice: cardiovascular effects and the role of cardiovascular epidermal growth factor receptor. Sci. Rep. 4:7430
118. Eckel RH, Kahn R, Robertson RM, Rizza RA. 2006. Preventing cardiovascular disease and diabetes: A call to action from the American Diabetes Association and the American Heart Association. Circulation 113:2943-46
119. Prada PO, Ropelle ER,Mourao RH, de Souza CT, Pauli JR, et al. 2009. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fedmice. Diabetes 58:2910-19
120. Grisanti LA, Repas AA, Talarico JA, Gold JI, Carter RL, et al. 2015. Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic adrenergic receptor stimulation. Am. J. Physiol. Heart Circ. Physiol. 308:H316-30
121. Chen B, Bronson RT, Klaman LD,Hampton TG,Wang JF, et al. 2000. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 24:296-99
122. Barrick CJ, Yu M, Chao HH, Threadgill DW. 2008. Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice. Toxicol. Appl. Pharmacol. 228:315-25
123. Barrick CJ, Roberts RB, Rojas M, Rajamannan NM, Suitt CB, et al. 2009. Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am. J. Physiol. Heart Circ. Physiol. 297:H65-75
124. Benter IF, Juggi JS, Khan I, Yousif MH, Canatan H, Akhtar S. 2005. Signal transduction mechanisms involved in cardiac preconditioning: role of Ras-GTPase, Ca2+/calmodulin-dependent protein kinase II and epidermal growth factor receptor. Mol. Cell Biochem. 268:175-83
125. Forster K, Kuno A, Solenkova N, Felix SB, Krieg T. 2007. The opioid receptor agonist DADLE at reperfusion protects the heart through activation of pro-survival kinases viaEGFreceptor transactivation. Am. J. Physiol. Heart Circ. Physiol. 293:H1604-8
126. Akhtar S, Yousif MH, Chandrasekhar B, Benter IF. 2012. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemiareperfusion injury. PLOS ONE 7:e39066
127. Feng M, Xiang JZ, Ming ZY, Fu Q, Ma R, et al. 2012. Activation of epidermal growth factor receptor mediates reperfusion arrhythmias in anaesthetized rats. Cardiovasc. Res. 93:60-68
128. Hammoud L, Lu X, Lei M, Feng Q. 2011. Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab. Basic Res. Cardiol. 106:459-71
129. Zhuang S, Liu N. 2014. EGFR signaling in renal fibrosis. Kidney Int. Suppl. 4:70-74
130. Uchiyama-Tanaka Y,Matsubara H, Nozawa Y,Murasawa S,Mori Y, et al. 2001. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int. 60:2153-63
131. Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, et al. 2002. Involvement of HBEGF and EGF receptor transactivation in TGF-mediated fibronectin expression in mesangial cells. Kidney Int. 62:799-808
132. UttarwarL, Peng F,WuD,Kumar S, Gao B, et al. 2011. HB-EGFreleasemediates glucose-induced activation of the epidermal growth factor receptor in mesangial cells. Am. J. Physiol. Ren. Physiol. 300:F921-31
133. Taniguchi K, Xia L, Goldberg HJ, Lee KW, Shah A, et al. 2013. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes 62:3874-86
134. Huang S, Zhang A, Ding G, Chen R. 2009. Aldosterone-induced mesangial cell proliferation ismediated by EGF receptor transactivation. Am. J. Physiol. Ren. Physiol. 296:F1323-33
135. DeyM, Baldys A, Sumter DB, Gooz P, Luttrell LM, et al. 2010. Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement. J. Pharmacol. Exp. Ther. 334:775-83
136. Chen J, Chen JK, Neilson EG, Harris RC. 2006. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J. Am. Soc. Nephrol. 17:1615-23
137. Chen J, Chen JK,Harris RC. 2012. Angiotensin II induces epithelial-to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway. Mol. Cell. Biol. 32:981-91
138. Zhuang S, Yan Y, Han J, Schnellmann RG. 2005. p38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation of renal epithelial cells after oxidant injury. J. Biol. Chem. 280:21036-42
139. Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, Ramos AM, Eguchi S, et al. 2013. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. J. Pathol. 231:480-94
140. Lee YJ, Han HJ. 2008. Albumin-stimulated DNA synthesis is mediated by Ca2+/PKC as well as EGF receptor-dependent p44/42 MAPK and NF-B signal pathways in renal proximal tubule cells. Am. J. Physiol. Ren. Physiol. 294:F534-41
141. Reich H, Tritchler D, Herzenberg AM, Kassiri Z, Zhou X, et al. 2005. Albumin activates ERK via EGF receptor in human renal epithelial cells. J. Am. Soc. Nephrol. 16:1266-78
142. SinghAB, Sugimoto K, HarrisRC. 2007. Juxtacrine activation of epidermal growth factor (EGF) receptor by membrane-anchored heparin-binding EGF-like growth factor protects epithelial cells from anoikis while maintaining an epithelial phenotype. J. Biol. Chem. 282:32890-901
143. Arar M, Zajicek HK, Elshihabi I, Levi M. 1999. Epidermal growth factor inhibits Na-Pi cotransport in weaned and suckling rats. Am. J. Physiol. 276:F72-78
144. GroenestegeWM, Thebault S, van der Wijst J, van den BergD, Janssen R, et al. 2007. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J. Clin. Investig. 117:2260-67
145. Grossmann C, Freudinger R, Mildenberger S, Krug AW,Gekle M. 2004. Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am. J. Physiol. Ren. Physiol. 286:F1226-31
146. McEneaney V,Harvey BJ, ThomasW. 2007. Aldosterone rapidly activates protein kinaseDvia a mineralocorticoid receptor/EGFR trans-activation pathway in theM1 kidneyCCDcell line. J. Steroid Biochem. Mol. Biol. 107:180-90
147. Capdevila J, Wang W. 2013. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr. Opin. Nephrol. Hypertens. 22:163-69
148. Chen JK,Capdevila J, HarrisRC. 2002. Heparin-bindingEGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. PNAS 99:6029-34
149. Zhao H, Tian W, Tai C, Cohen DM. 2003. Hypertonic induction of COX-2 expression in renal medullary epithelial cells requires transactivation of the EGFR. Am. J. Physiol. Ren. Physiol. 285:F281-88
150. Wang Z, Chen JK,Wang SW, Moeckel G, Harris RC. 2003. Importance of functional EGF receptors in recovery from acute nephrotoxic injury. J. Am. Soc. Nephrol. 14:3147-54
151. Chen J, Chen JK, Harris RC. 2012. Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury. Kidney Int. 82:45-52
152. Tang J, LiuN, Tolbert E, Ponnusamy M, Ma L, et al. 2013. Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am. J. Pathol. 183:160-72
153. Bollee G, Flamant M, Schordan S, Fligny C, Rumpel E, et al. 2011. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat. Med. 17:1242-50
154. Francois H, Placier S, FlamantM, Tharaux PL, Chansel D, et al. 2004. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J. 18:926-28
155. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, et al. 2005. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat. Med. 11:867-74
156. Che Q, Carmines PK. 2002. Angiotensin II triggers EGFR tyrosine kinase-dependent Ca2+ influx in afferent arterioles. Hypertension 40:700-6
157. Wassef L, Kelly DJ, Gilbert RE. 2004. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int. 66:1805-14
158. ZhangMZ, Wang Y, Paueksakon P, Harris RC. 2014. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 63:2063-72
159. Chen J, Chen JK,Harris RC. 2015. EGF receptor deletion in podocytes attenuates diabetic nephropathy. J. Am. Soc. Nephrol. 26:1115-25
160. Terzi F, BurtinM, Hekmati M, Federici P, Grimber G, et al. 2000. Targeted expression of a dominantnegative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J. Clin. Investig. 106:225-34
161. Liu N, Guo JK, Pang M, Tolbert E, Ponnusamy M, et al. 2012. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J. Am. Soc. Nephrol. 23:854-67
162. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. 2000. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 57:33-40
163. Chen MH, Kerkela R, Force T. 2008. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118:84-95
164. Grimminger F, Schermuly RT, Ghofrani HA. 2010. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat. Rev. Drug Discov. 9:956-70
165. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, et al. 2007. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study. Lancet Oncol. 8:387-94
166. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. 2007. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am. J. Kidney Dis. 50:203-18
167. Morange PE, Tregouet DA, Godefroy T, Saut N, Bickel C, et al. 2008. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: The AtheroGene study. J. Mol. Med. 86:1153-61
168. Moss ML, Sklair-Tavron L,Nudelman R. 2008. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 4:300-9
169. Kwok HF, Botkjaer KA, Tape CJ, Huang Y, McCafferty J, Murphy G. 2014. Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. Protein Eng. Des. Sel. 27:179-90
170. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, et al. 2005. Tumor necrosis factor-convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndromecoronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280:30113-19
171. Santos RA. 2014. Angiotensin-(1-7). Hypertension 63:1138-47